Recent SEC filings provide updated financial and operational disclosures for Translational Development Acquisition Corp. No recent public news coverage is available.

• The company filed an amended annual report on Form 10-K/A for the fiscal year ended December 31, 2025, disclosing that disclosure controls and procedures were not effective as of that date, while internal control over financial reporting was effective [S1].
• As of March 31, 2026, the company reported cash and cash equivalents of $24.63 million, current assets of $75.3 million, current liabilities of $861.1 million, a current ratio of 0.09, and a cash ratio of 0.03 [S2].
• The company reported net income of approximately $1.33 million for the quarter ended March 31, 2026 [S2].
• The company has a non-interest bearing promissory note from its Sponsor for up to $2 million for working capital, repayable upon consummation of a business combination or forgiven if no business combination occurs [S2].
• Management reported no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected the controls [S1].

The company’s public listing and capital structure provide a platform to pursue business combinations that could create shareholder value. The presence of a working capital loan from the Sponsor supports operational readiness. Management’s assessment of effective internal controls over financial reporting indicates a level of organizational control. The company’s net income reported in the latest quarter suggests some operational activity or income generation prior to a business combination.

The company’s liquidity ratios are low, reflecting significant current liabilities relative to current assets, which may constrain operational flexibility. Disclosure controls and procedures were assessed as not effective as of December 31, 2025, indicating potential risks in timely and accurate disclosure. The company’s business model depends entirely on completing a business combination, which carries execution risk and uncertainty. Failure to consummate a business combination could result in the promissory note being forgiven and limited operational prospects.

As a special purpose acquisition company, TDAC’s moat is primarily derived from its ability to identify and consummate a business combination with a target company. The company’s structure as a SPAC provides access to capital through its trust account and public listing, enabling it to pursue acquisition opportunities. However, the company does not have operating business assets or proprietary technology at this stage. Its competitive position depends on management’s execution in completing a value-creating business combination and the terms of such transaction.

• Business Combination Execution Risk: The company’s ability to create value depends on successfully identifying and completing a business combination. Failure to do so could materially affect its financial position and prospects.
• Liquidity Constraints: The company’s current ratio of 0.09 and cash ratio of 0.03 as of March 31, 2026, indicate limited liquidity relative to current liabilities, which may impact operational flexibility.
• Disclosure Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of December 31, 2025, which may increase the risk of delayed or inaccurate disclosures.
• Dependence on Sponsor Financing: The company relies on a non-interest bearing promissory note from its Sponsor for working capital, which is repayable only upon consummation of a business combination or forgiven otherwise, indicating dependence on Sponsor support.

• Translational Development Acquisition Corp. is a Cayman Islands-incorporated special purpose acquisition company (SPAC) listed on Nasdaq under the ticker TDAC.
• The company’s securities include Units (each consisting of one Class A ordinary share and one-half of one redeemable warrant), Class A ordinary shares, and redeemable warrants exercisable at $11.50 per share.
• As of March 30, 2026, the company had 17,250,000 Class A ordinary shares and 4,657,500 Class B ordinary shares issued and outstanding.
• The company’s principal executive office is located in New York, New York.
• The company is an emerging growth company and a smaller reporting company under SEC definitions.
• The company’s business model involves completing a business combination (merger, share exchange, asset acquisition, or similar) with one or more businesses or entities.
• The company has a promissory note loan agreement with its Sponsor (TDAC Partners LLC) for up to $2 million for working capital, non-interest bearing and repayable upon consummation of a business combination or forgiven if no business combination occurs.
• As of March 31, 2026, the company reported cash and cash equivalents of $24.63 million and current assets of $75.3 million, with current liabilities of $861.1 million, resulting in a current ratio of 0.09 and a cash ratio of 0.03.
• The company reported net income of approximately $1.33 million for the quarter ended March 31, 2026.
• Management assessed internal control over financial reporting as effective as of December 31, 2025, although disclosure controls and procedures were concluded not effective as of that date.
• There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected the controls.
• The company’s filings include detailed exhibits such as Memorandum and Articles of Association, promissory notes, registration rights agreements, and administrative services agreements.